Additional file 1 of Comparative proteomic profiling of plasma exosomes in lung cancer cases of liver and brain metastasis
Sini Li(Chinese Academy of Sciences), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Chao Wang(McLean Hospital), Xue Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan He(Chinese Academy of Medical Sciences & Peking Union Medical College), Hua Bai(Chinese Academy of Medical Sciences & Peking Union Medical College), Lihui Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yufeng Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Zixiao Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Yuan(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Qu(Sun Yat-sen University)
Cited by 0
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
|Journal of Clinical Oncology|2023|386
Molecular Design Strategy to Construct the Near-Infrared Fluorescent Probe for Selectively Sensing Human Cytochrome P450 2J2
|Journal of the American Chemical Society|2018|164